Results 191 to 200 of about 436,571 (380)
Advanced Science, EarlyView.An integrative analysis combining in vitro genome‐wide immune screens, in vivo ICB screens, and clinical data mining identifies METTL5 as a key tumor‐intrinsic immune factor. Mechanistic studies further reveal the importance of the METTL5‐ATF4‐SLC7A11/SLC3A2‐ferroptosis axis in modulating antitumor immune responses. These findings highlight METTL5 as a
Jiakai Hou +30 more
wiley +1 more source
The immunological synapse of CTL contains a secretory domain and membrane bridges.
Immunity, 2001 J. Stinchcombe +3 more
semanticscholar +1 more source
Engineering Bacteria as Living Therapeutics in Cancer Therapy
Advanced Science, EarlyView.Through synthetic biology approaches, natural bacteria can be genetically programmed into multifunctional living therapeutics. These engineered bacteria are capable of secreting anti‐tumor factors, displaying tumor‐associated antigens on their surface, or undergoing programmed self‐lysis to release therapeutic cargo.
Jiangfeng Chen +6 more
wiley +1 more source
Therapy‐Induced ECM Remodeling Creates a Transient Immune Barrier in Residual Melanoma
Advanced Science, EarlyView.BRAF/MEK inhibition promotes extracellular matrix (ECM) accumulation and remodeling during therapy‐tolerant residual disease, limiting CD8⁺ T cell access to tumor cells. Targeting ECM accumulation restores CD8⁺ T cell infiltration, enhances their intratumoral distribution, and delays therapeutic resistance.
Chia‐Hsin Hsu +6 more
wiley +1 more source
Advanced Science, EarlyView.Preparation of a biopolymer‐based immune implant (BI) for the sustained release of R848 and oxaliplatin (OXA), enabling immune activation and preventing recurrence after radiofrequency ablation (RFA) treatment in hepatocellular carcinoma (HCC). Abstract Hepatocellular carcinoma (HCC) remains a global challenge due to limited therapies and high ...
Yuezhan Shan +9 more
wiley +1 more source
IL-15 stimulates the expansion of AIDS virus-specific CTL. [PDF]
, 1996 Takuya Kanai +3 more
openalex +1 more source
Targeted Degradation of sGRP78 Alleviates the Immunosuppressive Tumor Microenvironment
Advanced Science, EarlyView.Soluble GRP78 (sGRP78) is identified as a novel tumor‐derived soluble factor that induces regulatory T cells (Treg). sGRP78 serves as an excellent serological biomarker for predicting the efficacy of neoadjuvant therapy in breast cancer patients. sGRP78 specifically binds to B cells, inducing the expression of IL‐10 and PD‐L1, thereby promoting Treg ...
Zhenghao Wu +10 more
wiley +1 more source